Search Result

Results for "

Drug-resistant strains

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (8) ATP Synthase (1) Bacterial (56) Beta-lactamase (2) Cytochrome P450 (2) DNA Methyltransferase (1) DNA/RNA Synthesis (5) Elastase (1) Endogenous Metabolite (1) Environmental Pollutants (1) Farnesyl Transferase (1) Fungal (3) HBV (4) HCV (2) HCV Protease (2) HDAC (1) HIV (8) HIV Integrase (1) HIV Protease (2) HSV (2) Isotope-Labeled Compounds (1) mTOR (1) NF-κB (1) Nucleoside Antimetabolite/Analog (2) p38 MAPK (1) Parasite (14) PDI (1) Penicillin-binding protein (PBP) (1) Ras (1) Reference Standards (5) Ribosomal S6 Kinase (RSK) (1) Succinate Dehydrogenase (1) Topoisomerase (2)
By Research Areas:	Cancer (7) Infection (85) Inflammation/Immunology (8) Metabolic Disease (2) Neurological Disease (1)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0402

Artemether 3 Publications Verification Dihydroqinghaosu methyl ether; Dihydroartemisinin methyl ether; SM224	Parasite	Infection Inflammation/Immunology Cancer
Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria .

HY-B1268

Docusate Sodium 2 Publications Verification Dioctyl sulfosuccinate sodium salt	Environmental Pollutants HSV	Others
Docusate Sodium (Dioctyl sulfosuccinate sodium salt) is one of the main components in stool softeners. Docusate Sodium is a sulfated surfactant and may inactivate viral pathogens by disrupting viral envelopes and/or denaturing/disassociating proteins. Docusate Sodium is effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2. Docusate Sodium is an obesogen. Docusate Sodium with developmental exposure leads to increased adult adiposity, inflammation, metabolic disorder and dyslipidemia in offspring fed a standard diet in mice .

HY-B1228

Ribostamycin sulfate 1 Publications Verification Vistamycin sulfate	Antibiotic PDI	Infection
Ribostamycin sulfate (Vistamycin sulfate) is a broad-spectrum aminoglycoside Antibiotic with bactericidal activity against Gram-positive cocci, Gram-negative cocci, bacilli, and drug-resistant strains. Ribostamycin sulfate also acts as an inhibitor of protein disulfide isomerase (PDI), with a binding constant K_D of 319 μM for bovine PDI. Ribostamycin sulfate targets bacterial 16S ribosomal RNA and the 30S ribosomal subunit, causing translational misreading and thereby inhibiting bacterial protein synthesis. Ribostamycin sulfate disrupts the integrity of bacterial cell membranes, induces membrane pore formation, and leads to bacterial death. Ribostamycin sulfate can be used in studies related to bacterial infections .

HY-A0248B

Polymyxin B2	Antibiotic Bacterial	Infection
Polymyxin B2 is a polypeptide antibiotic that has antibacterial activity, particularly against gram-negative bacteria. Polymyxin B2 kills the bacteria by binding to lipopolysaccharide molecules on the bacterial cell membrane, disrupting the integrity of the cell membrane and causing the cell contents to leak. Polymyxin B2 can be used in antibiotic development and treatment of drug-resistant strains .

HY-125576

Griselimycin	Bacterial	Infection
Griselimycin is a cyclic lipopeptide produced by Streptomyces. Griselimycin specifically binds to the sliding clamp of bacterial DNA polymerase and does not interact with human PCNA. Griselimycin exhibits potent antibacterial activity against Mycobacterium tuberculosis (including drug-resistant strains) and a variety of Gram-negative bacteria .

HY-P10233A

SAAP 148 TFA	Bacterial	Infection
SAAP 148 TFA is a synthetic antimicrobial peptide (bacteria) that interacts with and disrupts the lipid bilayer of bacterial cytoplasmic membranes, thereby inducing changes in membrane permeability and bacterial death. SAAP 148 TFA kills drug-resistant, multidrug-resistant and persister bacterial strains, inhibits biofilm formation, eliminates established biofilms, and blocks bacterial colonization on implant surfaces. SAAP 148 TFA retains its activity after modification or immobilization, exhibits variable cytotoxicity in different human cell models, and shows reduced efficacy in protein-rich environments. SAAP 148 TFA can be used in infection-related research .

HY-103249

Reutericyclin Reutericycline	Bacterial	Infection Metabolic Disease
Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .

HY-N1050

Zederone	mTOR Ribosomal S6 Kinase (RSK) Bacterial	Infection Neurological Disease Cancer
Zederone is a sesquiterpene. Zederone inhibits ovarian cancer cell proliferation through mTOR/p70s6K signalling pathway. Zederone inhibits CYP activities with IC₅₀s of 2.9 μM (CYP2B6), 9.2 μM (CYP2C9), 11,2 μM (CYP2C19) and >30 μM (CYP1A2 and CYP2D6). Zederone is hepatotoxic with LD₅₀ value at 24 hours in mice of approximately 223 mg/kg and cytotoxic against the KG1a cell line. Zederone shows antibacterial activity against a number of multi-drug resistant and Methicillin (HY-121544)-resistant Staphylococcus aureus strain. Zederone shows cognition improving capacity and assists in the modulation of gut bacterial dysbiosis .

HY-100358

AQ-13 dihydrochloride	Parasite	Infection
AQ-13 dihydrochloride is an aminoquinoline antimalarial agent that is effective against drug-resistant strains of Plasmodium falciparum.

HY-B1268R

Docusate Sodium (Standard) Dioctyl sulfosuccinate sodium salt (Standard)	Reference Standards HSV	Others
Docusate (Sodium) (Standard) is the analytical standard of Docusate (Sodium). This product is intended for research and analytical applications. Docusate Sodium (Dioctyl sulfosuccinate sodium salt) is one of the main components in stool softeners. Docusate Sodium is a sulfated surfactant and may inactivate viral pathogens by disrupting viral envelopes and/or denaturing/disassociating proteins. Docusate Sodium is effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2. Docusate Sodium is an obesogen. Docusate Sodium with developmental exposure leads to increased adult adiposity, inflammation, metabolic disorder and dyslipidemia in offspring fed a standard diet in mice .

HY-N7634

Tectol	Farnesyl Transferase Parasite	Infection Cancer
Tectol, isolated from Lippia sidoides, exhibits significant activity against human leukemia cell lines HL60 and CEM . Tectol is a farnesyltransferase (FTase) inhibitor with IC₅₀s of 2.09 and 1.73 μM for human and T. brucei FTase, respectively. Tectol inhibits drug-resistant strain of P. falciparum (FcB1) with an IC₅₀ of 3.44 μM .

HY-P10233

SAAP 148	Bacterial	Infection
SAAP 148 is a synthetic antimicrobial peptide (bacteria) that interacts with and disrupts the lipid bilayer of bacterial cytoplasmic membranes, thereby inducing changes in membrane permeability and bacterial death. SAAP 148 kills drug-resistant, multidrug-resistant and persister bacterial strains, inhibits biofilm formation, eliminates established biofilms, and blocks bacterial colonization on implant surfaces. SAAP 148 retains its activity after modification or immobilization, exhibits variable cytotoxicity in different human cell models, and shows reduced efficacy in protein-rich environments. SAAP 148 can be used in infection-related research .

HY-N10430

Patentiflorin A	HIV	Infection
Patentiflorin A is a potent, broadspectrum HIV-1 inhibitor. Patentiflorin A also inhibits HIV drug-resistant strains .

HY-172734

FG-2101	Bacterial	Infection
FG-2101 is a selective and orally active non-hydroxamate LpxC inhibitor with an IC₅₀ of ~1 nM. FG-2101 exhibits exquisite selectivity over other bacterial and human metalloenzymes. FG-2101 can be used for the study of Gram-negative bacteria infections including drug-resistant strains .

HY-144341

DprE1-IN-1	Bacterial	Infection
DprE1-IN-1 is a potent, orally active DprE1 inhibitor with favorable hepatocyte stability, low cytotoxicity and low hERG channel inhibition. DprE1-IN-1 displays potent activity against both agent-susceptible and clinically isolated drug-resistant Tuberculosis strains with MICs10 CFU reduction in macrophages.

HY-178347

Debio 1453	Bacterial	Infection
Debio 1453 is a bactericidal FabI inhibitor potent against N. gonorrhoeae (IC₅₀ = 0.6 nM), including drug-resistant strains. Debio 1453 demonstrates a low propensity for resistance selection and is effective in eradicating both planktonic and intracellular bacteria through a mechanism of concurrently inhibiting FabI and engaging the non-mutable NADH cofactor. Debio 1453 clears antibiotic-resistant N. gonorrhoeae infection in a murine vaginal model. Debio 1453 can be used for gonorrhoea research .

HY-109014

Tenofovir exalidex CMX-157	HIV HBV Nucleoside Antimetabolite/Analog	Infection
Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. Tenofovir exalidex is active against all major subtypes of HIV-1 and HIV-2 in fresh human PBMCs and against all HIV-1 strains evaluated in monocyte-derived macrophages, with EC₅₀s ranging between 0.2 and 7.2 nM. CMX157 is orally available and has no apparent toxicity. Tenofovir exalidex also shows antiviral activity against HBV .

HY-105048A

Omiganan pentahydrochloride	Bacterial	Infection
Omiganan pentahydrochloride is a cationic peptide compound with a broad antibacterial profile. Omiganan pentahydrochloride is capable of inhibiting a variety of bacteria, including yeast, and is active against both gram-positive and gram-negative bacteria. Omiganan pentahydrochloride is able to interact with the bacterial cell membrane, causing the destruction of the cell membrane and the death of the bacteria. Omiganan pentahydrochloride can be used for the study of antimicrobial activity against pathogens commonly associated with catheter-associated infections, including strains with drug-resistant phenotypes .

HY-W264454

Antibacterial agent 303	Bacterial	Infection
Antibacterial agent 303 (compound 3) is an antibacterial agent exhibiting potent antibacterial activity against MDR strains, with MICs of 10 and 100 µg/mL against Pseudomonas aeruginosa MDR1 and Staphylococcus aureus MDR strains, respectively. Antibacterial agent 303 displays strong binding affinities to E. coli DNA gyrase and Candida albicans lanosterol 14α-demethylase. Antibacterial agent 303 can be used for drug-resistant infections research .

HY-111746

CWHM-1008 1 Publications Verification	Parasite	Infection
CWHM-1008 is a potent and orally active antimalarial agent, with EC₅₀ values of 46 and 21 nM against agent-sensitive Plasmodium falciparum 3D7 and drug-resistant Dd2 strains, respectively .

HY-178504

Lug-15	Bacterial	Infection
Lug-15 is a rapid bactericidal agent. Lug-15 exhibits strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Lug-15 demonstrates low hemolytic toxicity and significant therapeutic potential in various infection models. Lug-15 can be used for research on combating infections caused by multi-drug resistant bacteria .

HY-P11027

Thiazoplanomicin	Bacterial Antibiotic	Infection
Thiazoplanomicin (Compound 1) is a thiazolyl peptide antibiotic. Thiazoplanomicin can be isolated from the leaf-litter actinomycete Actinoplanes sp. MM794L-181F6. Thiazoplanomicin has potent antimicrobial activities against gonococcal strains (especially drug-resistant strains) and Gram-positive bacterium with MICs of 31.2-125 and 0.5-15.6 ng/mL, respectively. Thiazoplanomicin has no antibacterial activity against E.coli. Thiazoplanomicin can be used for bacterial infections research .

HY-102009

BB-83698	Bacterial	Infection
BB-83698 is a peptide deformylase (PDF) inhibitor. BB-83698 exhibits potent in vitro activity against Streptococcus pneumoniae, with a minimum inhibitory concentration (MIC) range of 0.06-0.25μg/mL. BB-83698 elevates the survival rate of mice regardless of whether the infecting strain carries resistance mechanisms. BB-83698 can be used for the study of diseases related to drug-resistant Streptococcus pneumoniae infections .

HY-12108

S 1360	HIV Integrase HIV	Infection
S 1360 is a potent and selective inhibitor of HIV-1 integrase. S 1360 inhibits the catalytic activity of purified integrase ( IC₅₀: 20 nM). The EC₅₀, and CC₅₀ of S 1360 in MTT assay (MT-4 cells infected with HIV-1 IIIB) are 200 nM and 12 μM, respectively. S 1360 has antiviral activity against both X4 tropic and R5 tropic strains, as well as NRTI, NNRTI and PI drug-resistant variants .

HY-19234

FK-041	Antibiotic Bacterial Penicillin-binding protein (PBP) Beta-lactamase	Infection
FK-041 is an orally active cephalosporin antibiotic with high affinity for penicillin-binding proteins (PBPs). FK-041 exhibits broad-spectrum antibacterial activity, exerting potent antibacterial effects against Gram-positive bacteria, most Gram-negative bacteria, anaerobes, and so on. FK-041 also shows good efficacy against some drug-resistant strains such as penicillin-resistant Streptococcus pneumoniae. FK-041 is an antibacterial agent and can be used in the research of infectious diseases .

HY-19932

MK-2748	HCV Protease HCV	Infection
MK-2748 is a hepatitis C virus (HCV) NS3/4a protease inhibitor. MK-2748 exhibits broad-spectrum and potent antiviral activity, with nanomolar-level activity against all genotypes (gt1a-gt6) (IC₅₀ < 0.115 nM), showing only slightly weaker activity against gt3a (1.212 nM), and maintaining high inhibitory activity against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 can be used in the research of HCV infection .

HY-155190

Antitubercular agent-39	Bacterial	Infection
Antitubercular agent-39 (Compound P1) is a potent antitubercular agent. Antitubercular agent-39 is active against drug-resistant strains and drug-susceptible clinical isolates. Antitubercular agent-39 inhibits Mtb strain H37Rv with a MIC less than 1 μM .

HY-P11102

Temporin-SHa	Bacterial Fungal HIV Parasite	Infection Cancer
Temporin-Sha is an antibacterial peptide with extensive biological activity. Temporin-Sha exhibits broad-spectrum antibacterial activity (e.g., against L. ivanovii, MIC = 6.25 μM), and is effective against Gram-negative bacteria (such as Escherichia coli, MIC = 10 μM), including drug-resistant strains (such as Methicillin (HY-121544)-resistant Staphylococcus aureus). Temporin-Sha also has inhibitory effects on Candida albicans (MIC = 25 μM), Saccharomyces cerevisiae (MIC = 12 μM), the pre-flagellated and non-flagellated forms of Leishmania infantum (IC₅₀ = 5-20 μM), and Trypanosoma cruzi (IC₅₀ = 17 μM). Temporin-Sha exhibits antiviral activity against HSV-1 and has anti-cancer effects (cytotoxicity against breast cancer cells MCF-7 and lung cancer cells H460, etc.) .

HY-A0248C

Polymyxin B2 Sulfate	Antibiotic Bacterial	Infection
Polymyxin B2 Sulfate is a polypeptide antibiotic that has antibacterial activity, particularly against gram-negative bacteria. Polymyxin B2 Sulfate kills the bacteria by binding to lipopolysaccharide molecules on the bacterial cell membrane, disrupting the integrity of the cell membrane and causing the cell contents to leak. Polymyxin B2 Sulfate can be used in antibiotic development and treatment of drug-resistant strains .

HY-178952

Anti-infective agent 12	Bacterial	Infection
Anti-infective agent 12 (Compound A09) is a competitive inhibitor of type I signal peptidease (SPase I), with an IC₅₀ of 4.475 μM and a K_d of 16.3 μM. Anti-infective agent 12 has the ability to disrupt bacterial membranes and remove biofilms. Anti-infective agent 12 exhibits potent bactericidal activity against Gram-positive bacteria, with MIC values of 4, 4, 8, and 8 μg/mL for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Streptococcus suis, respectively. Anti-infective agent 12 remains effective against multi-drug resistant strains, but has weaker activity against Gram-negative bacteria (such as Escherichia coli and Salmonella), with MIC values > 64 μg/mL. Anti-infective agent 12 has low hemolytic activity and shows significant efficacy in mouse skin infection models .

HY-N15059

Cissetin	Bacterial	Infection
Cissetin shows activity against Gram-positive bacteria, including drug-resistant strains .

HY-122073

Furalazine	Bacterial	Infection
Furalazine is an antimicrobial agent. Furalazine shows activity against drug-resistant strains of cholera bacteria. Furalazine has the potential for the research of cholera .

HY-107468

PL-100	HIV Protease	Infection Inflammation/Immunology
PL-100 is a potent HIV-1 protease inhibitor with a K_i of 36 pM and an EC₅₀ of 16 nM. PL-100 inhibits viral replication by suppressing HIV-1 protease activity and demonstrates excellent antiviral efficacy against drug-resistant HIV strains. PL-100 can be used in research on drug-resistant HIV disease .

HY-N0402R

Artemether (Standard) Dihydroqinghaosu methyl ether (Standard); Dihydroartemisinin methyl ether (Standard); SM224 (Standard)	Reference Standards Parasite	Infection Inflammation/Immunology Cancer
Artemether (Standard) is the analytical standard of Artemether. This product is intended for research and analytical applications. Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria .

HY-144215

TLR8 agonist 4	HBV	Inflammation/Immunology
TLR8 agonist 4 showed effective inhibition on wild-type and drug-resistant (lamivudine and entecavir) HBV strains. The IC₅₀ values are 0.15 and 0.10 respectively μM.

HY-145912

RYL-552S	Parasite	Infection Inflammation/Immunology
RYL-552S kills drug-resistant strains of Plasmodium falciparum. RYL-552S can efficiently kill asexual blood-stage parasites in vitro .

HY-N8388

Collinin	Bacterial	Infection
Collinin is a anti-tubercular agent, it can be isolated from leaves of Z. schinifolium. Collinin has an excellent anti-tuberculosis effect against multidrug-resistant (MDR), extensively drug-resistant (XDR) strains .

HY-161689

Antibacterial agent 220	Bacterial	Infection
Antibacterial agent 220 is a potent antibacterial agent that can directly destroy bacterial cell membranes. Antibacterial agent 220 effectively combats Gram-positive and and Gram-negative pathogens, including drug-resistant strains .

HY-P10526

CRAMP (1-39)	Bacterial	Infection
CRAMP (1-39) is an antimicrobial peptide. CRAMP (1-39) has shown potent bactericidal effects against multiple strains of Neisseria meningitidis in vitro. CRAMP (1-39) can be used to study drug-resistant bacterial infections .

HY-147988

DNA Gyrase-IN-5	DNA/RNA Synthesis Bacterial	Infection
DNA Gyrase-IN-5 (Compound 8I-w) is a potent DNA gyrase inhibitor with an IC₅₀ of 0.10 μM. DNA Gyrase-IN-5 shows antibacterial activities against wild type and drug-resistant strains .

HY-151599

Pks13-TE inhibitor 3	Bacterial	Infection
Pks13-TE inhibitor 3 (compound 23) is a 13-Thioesterase (Pks13-TE) inhibitor (IC₅₀=1.55 μM). Pks13-TE inhibitor 3 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0625-0.25 μg/mL). Pks13-TE inhibitor 3 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .

HY-151598

Pks13-TE inhibitor 2	Bacterial	Infection
Pks13-TE inhibitor 2 (compound 32) is a 13-Thioesterase (Pks13-TE) inhibitor (IC₅₀=1.30 μM). Pks13-TE inhibitor 2 shows good anti-tuberculosis activity against both agent-sensitive and drug-resistant Mtb strains (MIC=0.0039-0.0078 μg/mL). Pks13-TE inhibitor 2 can be used in studies of multidrug-resistant TB and extensively drug-resistant TB .

HY-137960

O,O-Dimethyl-cannabigerol	Bacterial	Inflammation/Immunology Cancer
O,O-Dimethyl-cannabigerol is a natural product from Cannabis sativa. O,O-Dimethyl-cannabigerol has an antibacterial effect on drug-resistant strains of Staphylococcus aureus (MIC ranging from 1 to 2 μg/mL) . O,O-Dimethyl-cannabigerol is a nonpsychoactive constituent .

HY-W768856

Artemether-13C,d3 Dihydroqinghaosu methyl ether-¹³C,d₃; Dihydroartemisinin methyl ether-¹³C,d₃; SM224-¹³C,d₃	Isotope-Labeled Compounds Parasite	Infection Inflammation/Immunology Cancer
Artemether- ¹³C,d₃ (Dihydroqinghaosu methyl ether- ¹³C,d₃) is the deuterium and ¹³C-labeled Artemether (HY-N0402). Artemether is an anti-malarial compound that targets drug-resistant strains of falciparum malaria .

HY-147871

Antimycobacterial agent-3	Bacterial	Infection
Antimycobacterial agent-3 (Compound 1h) is an antimycobacterial agent against both agent-sensitive MTB strain H37Rv and drug-resistant clinical isolates (MIC: < 0.029–0.110 μM). Antimycobacterial agent-3 shows low cell cytotoxicity .

HY-114956

AT-61	HBV	Infection
AT-61 is a non nucleoside HBV replication inhibitor. AT-61 prevents the capsid formation of pre genomic RNA, resulting in the production of empty capsids. AT-61 has the activity of drug-resistant mutant strains. AT-61 can be used for research on hepatitis B virus infection .

HY-155510

DprE1-IN-5	Bacterial	Infection
DprE1-IN-5 (Compound 10) is a DprE1 inhibitor. DprE1-IN-5 has anti-TB activity against Mtb H37Rv strain (MIC: 4 μM). DprE1-IN-5 also has antimycobacterial activity against drug-resistant strains. DprE1-IN-5 has high microsomal stability .

HY-P10411

BING	Bacterial	Infection
BING is an antimicrobial peptide that can be isolated from Japanese medaka fish. BING shows a broad-spectrum toxicity against pathogenic bacteria including drug-resistant strains. BING induces a deregulation of periplasmic peptidyl-prolyl isomerases in gram-negative bacteria, and reduces the RNA level of cpxR, which plays a crucial role in the development of antimicrobial resistance .

HY-155511

DprE1-IN-6	Bacterial	Infection
DprE1-IN-6 (Compound 56) is a DprE1 inhibitor. DprE1-IN-6 has anti-TB activity against Mtb H37Rv strain (MIC: 1 μM). DprE1-IN-6 also has antimycobacterial activity against drug-resistant strains. DprE1-IN-6 has high microsomal stability and medium clearance .

HY-155512

DprE1-IN-7	Bacterial	Infection
DprE1-IN-7 (Compound 64) is a DprE1 inhibitor. DprE1-IN-7 has anti-TB activity against Mtb H37Rv strain (MIC: 1 μM). DprE1-IN-7 also has antimycobacterial activity against drug-resistant strains. DprE1-IN-7 has high microsomal stability and medium clearance .

Cat. No.	Product Name

HY-L940

Antiviral Lead-like compound library

5,813 compounds

Owing to the widespread transmission and frequent mutation of viral diseases, as well as the continuous emergence of new viruses and drug-resistant strains, antiviral drug development is facing increasingly stringent requirements. Antiviral compound libraries serve as important tools for drug screening, mechanism research and development, enabling the discovery and investigation of various antiviral drugs.

These compounds act through diverse antiviral mechanisms, targeting key steps in viral replication, assembly and invasion. They exert antiviral effects by inhibiting viral nucleic acid synthesis, blocking viral protein processing, and preventing viral binding to host cells. This library covers various types of antiviral compounds, including nucleosides, non-nucleosides, protease inhibitors and integrase inhibitors. It supports research on influenza virus, herpes virus, hepatitis virus, emerging respiratory viruses and other pathogens, and enables high-throughput screening of novel antiviral candidates to rapidly identify potential active compounds against diverse viruses. It also facilitates mechanistic studies to elucidate drug-target interactions and viral resistance mechanisms, and supports the screening of effective compounds against mutant strains for research on viral variation and drug resistance.

This antiviral library consists of 6,804 compounds with lead-like physicochemical properties. The core sources of the compounds include analogs of known antiviral molecues with a similarity score ≥ 0.6. MCE has collected more than 1450 antiviral molecules. As a small-molecule collection with both activity potential and structural modifiability, it provides strong support for antiviral drug research and development.

Cat. No.	Product Name	Target	Research Area